Champions Oncology (CSBR) director granted 25,460 options at $6.80

Champions Oncology (CSBR) insider activity: a director and 10% owner reported an award of derivative securities.

Rhea-AI Filing Summary

Champions Oncology (CSBR) insider activity: a director and 10% owner reported an award of derivative securities. On 11/05/2025, the reporting person acquired an option to purchase 25,460 shares of common stock at an exercise price of $6.80 per share, recorded as a Code A grant and held directly.

The options vest over twelve months in four dates—11/05/2025, 02/05/2026, 05/05/2026, and 08/05/2026—and are exercisable over ten years, with an expiration date of 11/05/2035.

Insider Trade Summary

Grant/Award: 25,460 shares

Grant/Award 1 txn

Insider TOBIN SCOTT R

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase Common Stock	25,460	$6.80	$173K

Holdings After Transaction: Option to purchase Common Stock — 25,460 contracts (Direct)

Footnotes (1)

1. F1. The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 5, 2025, February 5, 2026, May 5, 2026 and August 5, 2026, respectively.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CSBR report on Form 4?

An option grant for 25,460 shares of common stock at an exercise price of $6.80 per share on 11/05/2025.

Who is the reporting person in CSBR’s Form 4?

A Director and 10% Owner; the form is signed by Scott R. Tobin.

What is the vesting schedule for the CSBR options?

Vesting occurs on 11/05/2025, 02/05/2026, 05/05/2026, and 08/05/2026.

When do the CSBR options expire?

The options have an expiration date of 11/05/2035.

How many derivative securities were acquired and how are they held?

25,460 options were acquired and are held directly (D).

What transaction code is used in the filing?

Transaction code A, indicating an award or grant of derivative securities.

What security underlies the options in CSBR’s Form 4?

Each option is for Common Stock, totaling 25,460 underlying shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/07/2025 - 11:00 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TOBIN SCOTT R

(Last) (First) (Middle)

C/O CHAMPIONS ONCOLOGY, INC.

ONE UNIVERSITY PLAZA, SUITE 307

(Street)

HACKENSACK NJ 07601

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CHAMPIONS ONCOLOGY, INC. [ CSBR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase Common Stock	$6.8	11/05/2025		A		25,460		(1)	11/05/2035	Common Stock	25,460	$6.8	25,460	D

Explanation of Responses:

1. The options vest over a twelve month period and are exercisable over a ten year period, with vesting to occur on November 5, 2025, February 5, 2026, May 5, 2026 and August 5, 2026, respectively.

Remarks:

	/s/ Scott R. Tobin	11/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.